 |
|
Conference report highlights new research into drug delivery to treat eye disease
November 18, 2008Group explores alternatives to surgery and intravitreous injection
Rockville, MD - Researchers are investigating microneedles, nanoparticles and polymer carriers as potential new techniques to combat the leading cause of visual impairment and blindness in the United States, according to a report from the Third Annual ARVO/Pfizer Ophthalmics Research Institute Conference.
The report (http://www.iovs.org/cgi/content/full/49/11/4712) includes summaries from seven sessions on techniques for ocular drug delivery to the posterior segment of the eye and includes the findings of and opinions of more than 30 top ophthalmic researchers, brought together by the ARVO Foundation for Eye Research. The article in the November issue of Investigative Opthalmology & Visual Science defines the current research and the future needs for ocular drug delivery.
Diseases of the posterior segment of the eye are responsible for the majority of visual impairment and blindness cases in the United States, according to George Williams, MD. Until recently, these diseases were primarily treated with surgery, but recent developments in drug therapies have either replaced or complemented surgery.
But the challenge lies in delivering the drugs. Topical delivery such as ointments and drops are fairly ineffective, and delivery via intravitreous injection (an injection into the fluid in the behind the lens in the eye) can be hard on the patient. According to the report, "Improved drug delivery technologies that provide optimal pharmacokinetics, dose intervals and less invasive routes of administration are needed."
During the two-day event, John Heckenlively, MD, joined Jayakrishna Ambarti, MD, in a session on animal models of posterior ocular diseases. Allan Hoffman, ScD, discussed the design of polymer carriers for intracellular delivery of biomolecular drugs, such as peptides, proteins and nucleic acid drugs. His group is focused on using a family of acid-sensitive polymers to help deliver one of the latest drugs, silencing RNA (siRNA).
Another group of presenters discussed the use of nanoparticles, microbeads and microneedles. Mansoor M. Amiji, PhD, said that nanoparticles can help overcome barriers to drug delivery from the organ level to the subcellular level. Another research laboratory was investigating the effectiveness of hollow and solid microneedles that penetrate only hundreds of micrometers into the cornea or sclera to deliver drugs.
A safer alternative to direct intravitreous injections might be transscleral delivery into the vitreous using subconjunctival injections, said Michael Robinson, MD, adding that researchers needed a clear understanding of the dynamic barriers for the technique to work in treating retinal diseases. Another researcher in this area, Dayle H. Geroski, PhD, suggested that the relatively high permeability of the sclera offers great potential for transscleral drug delivery, especially for administration to the posterior part of the eye.
Other research focused on photodynamic therapy, which uses a photosensitizer agent that localizes more or less selectively to the target tissue and is activated by light, triggering chemical reactions that injure the target tissue.
Association for Research in Vision and Ophthalmology
Diseases of the posterior segment of the eye are responsible for the majority of visual impairment and blindness cases in the United States, according to George Williams, MD. Until recently, these diseases were primarily treated with surgery, but recent developments in drug therapies have either replaced or complemented surgery.
But the challenge lies in delivering the drugs. Topical delivery such as ointments and drops are fairly ineffective, and delivery via intravitreous injection (an injection into the fluid in the behind the lens in the eye) can be hard on the patient. According to the report, "Improved drug delivery technologies that provide optimal pharmacokinetics, dose intervals and less invasive routes of administration are needed."
During the two-day event, John Heckenlively, MD, joined Jayakrishna Ambarti, MD, in a session on animal models of posterior ocular diseases. Allan Hoffman, ScD, discussed the design of polymer carriers for intracellular delivery of biomolecular drugs, such as peptides, proteins and nucleic acid drugs. His group is focused on using a family of acid-sensitive polymers to help deliver one of the latest drugs, silencing RNA (siRNA).
Another group of presenters discussed the use of nanoparticles, microbeads and microneedles. Mansoor M. Amiji, PhD, said that nanoparticles can help overcome barriers to drug delivery from the organ level to the subcellular level. Another research laboratory was investigating the effectiveness of hollow and solid microneedles that penetrate only hundreds of micrometers into the cornea or sclera to deliver drugs.
A safer alternative to direct intravitreous injections might be transscleral delivery into the vitreous using subconjunctival injections, said Michael Robinson, MD, adding that researchers needed a clear understanding of the dynamic barriers for the technique to work in treating retinal diseases. Another researcher in this area, Dayle H. Geroski, PhD, suggested that the relatively high permeability of the sclera offers great potential for transscleral drug delivery, especially for administration to the posterior part of the eye.
Other research focused on photodynamic therapy, which uses a photosensitizer agent that localizes more or less selectively to the target tissue and is activated by light, triggering chemical reactions that injure the target tissue.
Association for Research in Vision and Ophthalmology
Eye Disease Current Events and Eye Disease News RSSResearchers find new way to attack inflammation in Graves' eye disease
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab.
Cataract surgery helps AMD patients; steroid improves DME; online eye health forum
This month's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy) reports on a national study that finds cataract surgery is likely to benefit patients with age-related macular degeneration (AMD) at all stages of the disease, on a clinical trial showing that the steroid triamcinolone may be effective in advanced diabetic macular edema (DME) patients when standard treatment fails, and on the public's use of two Academy-sponsored online eye health forums.
Experimental treatments restore partial vision to blind people
Two experimental treatments, a retinal prosthesis and fetal tissue transplant, restored some vision to people with blinding eye diseases. The findings, presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health, may lead to new treatments for the blind.
Cancer drug is no different in effectiveness as gold standard treatment for macular degeneration
Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
Toronto researchers discover novel circulation in human eye, new glaucoma treatment target
Researchers at the University of Toronto, St. Michael's Hospital and Sunnybrook Health Sciences Centre have discovered a previously unidentified form of circulation within the human eye which may provide important new insights into glaucoma, a leading cause of blindness.
International conference on endothelin
One of the most intriguing developments in recent medical science is the discovery of the human chemical endothelin (ET).
JDRF-funded studies show regular CGM use increases diabetes control for all age groups
The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors - six days per week or more - rather than the age of patients, and that benefits continue well past the time when people with type 1 diabetes begin using the devices - including experiencing fewer low blood sugar emergencies.
Elevated arginase levels contribute to vascular eye disease such as diabetic retinopathy
Elevated levels of the enzyme arginase contribute to vascular eye damage and Medical College of Georgia researchers say therapies to normalize its levels could halt progression of potentially blinding diseases such as diabetic retinopathy.
Anti-growth factor drugs raise hope and concern for treatment of children's eye diseases
A new class of antibody drugs may provide a powerful new tool for the treatment of eye diseases in children, but specialists need to be alert for the possibility of serious side effects, according to an editorial in the August Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus), published by Elsevier.
Natural Compound Stops Diabetic Retinopathy
Researchers at the University of Oklahoma Health Sciences Center have found a way to use a natural compound to stop one of the leading causes of blindness in the United States.
More Eye Disease Current Events and Eye Disease News Articles
 |
Thyroid Eye Disease: Understanding Graves\' Ophthalmopathy by Elaine A. Moore (Author) The only educational resource and guide for patients with Graves' Ophthalmopathy, an inflammatory eye disorder that often precedes, accompanies, or follows autoimmune thyroid disease. |
 |
PetAlive Eye-Heal for Pet Eye Infections by PetAlive Causes of infections include various bacteria, viruses like the Herpes virus, foreign material or irritants in the eye and even Lyme disease. Common signs and symptoms of eye infection in pets include squinting of the eye, watery or mucoid discharge, red or swollen conjunctiva (the pink part just inside the eyelids), the iris (colored part of the eye) may also appear dull or cloudy. Conventional treatment usually involves aspirin, corticosteroids, or other anti-inflammatory drugs for pain relief - as well as eye drops or ointments and topical or oral antibiotics. PetAlive Eye-Heal contains a blend of pure and natural ingredients in an herbal tincture and will effectively treat and prevent eye infections in dogs and cats as well as improve general eye and visual health. |
![Yoga for Eye Diseases [Swami Ramdev]](http://ecx.images-amazon.com/images/I/51RXS%2BAByYL._SL160_.jpg) |
Yoga for Eye Diseases [Swami Ramdev] |
 |
Hearts&Minds No-Stir Peanut Butter with Olive Oil and Omega-3Crunchy, 11.3 Ounce Bottles (Pack of 6) by Hearts&Minds Hearts&Minds LLC creates great tasting products thoughtfully made with the consumer's heart in mind by using heart healthy olive oil and omega-3 (EPA/DHA) to replace a portion of the fat in foods consumers love. Hearts&Minds® peanut butter helps con |
 |
Balanceuticals Clear Eye & Sharp Ear Dietary Supplement Capsules, 500 mg, 60-Count Bottles (Pack of 2) by Balanceuticals Dietary Supplement. 100% Natural. Made under Supervision by China Academy of Traditional Chinese Medicine. Made of extracts from astragalus root, pueraria root, seashore vitex, common peony root, cimicifuge, phellodendron, licorice, cnidium, Chinese angel |
 |
Please read this while I stare at your tits EYE EXAM CHART Logo Men's Hoodie Sweat Shirt Small thru 4XL by 99 Volts |
 |
Selling Your Disease (Alt. Mix) The Masked Musician (Primary Contributor) |
 |
The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease (Rhee, The Wills Eye Manual) by Justis P Ehlers (Editor), Chirag P Shah (Editor), Gregory L Fenton (Editor), Eliza N Hoskins (Editor), Heather N Shelsta (Editor) Now in full color and completely updated, the Fifth Edition of this best-selling manual is a reliable quick-reference guide for all clinicians who treat eye disorders. Every disorder encountered in the office, emergency room, or hospital is covered in concise outline format: symptoms, signs, work-up, treatment, and follow-up. Also included are chapters on differential diagnosis of ocular symptoms and signs, a section on current imaging modalities in ophthalmology, and a Pharmacopoeia. This edition features over 200 full-color photographs and includes the newest drugs, procedures, and treatment protocols. New topics covered include iridodialysis/cyclodialysis, shaken baby syndrome, crystalline keratopathy, refractive surgery complications, aberrant regeneration of the third nerve, venous... |
|
Living with Disease: Teens with Chronic Illness: Through Their Eyes DVD by Clearvue Glimpse the lives of three teenage girls living with challenging medical conditions. | |
 |
Wills Eye Manual (Software for download) by Skyscape Designed for the eye care provider who, in the midst of evaluating an eye problem, needs quick access to additional information. Includes the results of some of the recent clinical trials, such as the CRASH study. Newly adeed a number of new topics on iridodialysis/ cyclodialysis, sclopeteria, shaken baby syndrome, crystalline keratopathy, ptosis, familial exudative vitreoretinopathy, crystalline retinopathy, lens-induced glaucoma, polypoidal choroidal vasculopathy, ophthalmic acronyms, and an enhanced pharmacopoeia. Key Features * Instant access to current information on diagnosis and treatment of all eye disorders. * Valuable resource for residents, comprehensive opthalmologists, optometrists, emergency room physicians, prmiary care practitioners, medical students and other health care... |
| © 2009 BrightSurf.com |